NCT04409639 · OUTCOME

Progression-free Survival (PFS)

Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations · Source last updated 2026-07-21

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: up to 36 months after the start of therapy, the time of progression, initiation of alternative treatment or death, whichever came first

What was measured

Assessment of long-term efficacy

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denom Units Selected: Participants
description: Assessment of long-term efficacy
reporting Status: NOT_POSTED
time Frame: up to 36 months after the start of therapy, the time of progression, initiation of alternative treatment or death, whichever came first
title: Progression-free Survival (PFS)
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice